Continuation Study for Latozinemab

• Status: Enrolling by invitation
• Trial end date: 2027-11-30
• Target enrollment: 0
• Participant gender: All

Summary

Continuation study to provide continued access to latozinemab for participants who have previously participated in a latozinemab study

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Alector Inc.

Criteria

Inclusion Criteria:

• Written informed consent must be obtained and documented (from the participant or, where jurisdictions allow it, from their legal decision maker).

• Has successfully completed participation in their parent latozinemab study.

• Female participants must be nonpregnant and nonlactating.

• Male participants must agree to acceptable contraception use.

Exclusion Criteria:

• Known history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric, human, or humanized antibodies or fusion proteins.

• Clinically significant heart disease, liver disease or kidney disease. History or evidence of clinically significant brain disease other than FTD.